Ariad Pharmaceuticals (ARIA) Receiving Somewhat Favorable Press Coverage, Report Finds
Media coverage about Ariad Pharmaceuticals (NASDAQ:ARIA) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a coverage optimism score of 0.01 on Accern’s scale. Accern also gave media headlines about the pharmaceutical company an impact score of 45.9495371817665 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Ariad Pharmaceuticals (ARIA) traded up $0.04 during trading hours on Monday, reaching $23.99. The company had a trading volume of 7,220,900 shares, compared to its average volume of 15,701,480. Ariad Pharmaceuticals has a 1 year low of $4.67 and a 1 year high of $23.99. The company has a current ratio of 3.17, a quick ratio of 3.15 and a debt-to-equity ratio of -11.28.
ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/ariad-pharmaceuticals-aria-receiving-somewhat-favorable-press-coverage-report-finds/1729371.html.
About Ariad Pharmaceuticals
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Receive News & Ratings for Ariad Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.